Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Year To Remember For US Drug Launches

Executive Summary

A record-breaking 46 novel drugs and biologics were approved by FDA in 2017. The number of drugs that launched were plentiful and several were highly innovative, ushering in a new era of therapeutic breakthroughs. Turning pioneering medicines into commercial successes will be the test.


Related Content

New Active Substance First Launches Rebound In 2017
Roche's Ocrevus: A Rare First-Year Blockbuster
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
Quick Commercial Standouts Lacking Among 2016 US Launches
Novel Approvals Were Fewer But Faster At US FDA In 2016
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts